Everhart Financial Group Inc. lowered its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 22.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 746 shares of the company’s stock after selling 213 shares during the quarter. Everhart Financial Group Inc.’s holdings in IDEXX Laboratories were worth $308,000 as of its most recent filing with the SEC.
Other institutional investors have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories during the 4th quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC boosted its stake in IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the last quarter. Finally, Ashton Thomas Securities LLC acquired a new stake in IDEXX Laboratories during the 3rd quarter worth $37,000. Institutional investors and hedge funds own 87.84% of the company’s stock.
IDEXX Laboratories Stock Down 3.3 %
NASDAQ IDXX opened at $444.53 on Monday. The firm has a market cap of $36.40 billion, a PE ratio of 41.66, a P/E/G ratio of 3.47 and a beta of 1.37. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The business’s fifty day simple moving average is $430.95 and its 200-day simple moving average is $452.96. The company has a quick ratio of 1.03, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on IDXX
Insider Activity at IDEXX Laboratories
In related news, Director Sophie V. Vandebroek sold 344 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the sale, the director now directly owns 905 shares in the company, valued at approximately $380,498.20. The trade was a 27.54 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 13,330 shares of company stock worth $6,161,276. Company insiders own 2.11% of the company’s stock.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Stories
- Five stocks we like better than IDEXX Laboratories
- What to Know About Investing in Penny Stocks
- Symbotic Shares Down 37%—Is It Time for Bravery or Caution?
- How to Use the MarketBeat Dividend Calculator
- High-Yield Healthcare: 3 Stocks With Strong Dividends
- Market Cap Calculator: How to Calculate Market Cap
- Beyond the Bargain Bin: 3 Stocks Leading Discount Retail
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.